PMID- 12359744
OWN - NLM
STAT- MEDLINE
DCOM- 20021108
LR  - 20151119
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 62
IP  - 19
DP  - 2002 Oct 1
TI  - Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human 
      epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
PG  - 5405-7
AB  - Cyclooxygenase 2 (HER-2) (Cox-2), an inducible form of Cox, is overexpressed in 
      HER-2/neu-positive human breast cancers. The aim of this study was to determine 
      whether celecoxib, a selective Cox-2 inhibitor, protected against 
      HER-2/neu-induced experimental breast cancer. Cox-2 protein was detected in 
      breast carcinomas from mouse mammary tumor virus (MMTV)/neu mice. Treatment with 
      celecoxib (500 ppm) significantly reduced the incidence of mammary tumors in 
      MMTV/neu mice (P = 0.003) and caused about a 50% reduction in mammary 
      prostaglandin E2 (PGE2) levels. Because mammary glands from MMTV/neu mice 
      expressed all four PGE2 receptor subtypes, we speculate that signaling through 
      PGE2 receptors is important for mammary tumorigenesis. These results strengthen 
      the rationale for developing clinical trials to determine whether selective Cox-2 
      inhibitors possess anticancer properties in humans at risk for breast cancer.
FAU - Howe, Louise R
AU  - Howe LR
AD  - Department of Cell and Developmental Biology, Weill Medical College of Cornell 
      University, New York, New York 10021, USA. lrhowe@med.cornell.edu
FAU - Subbaramaiah, Kotha
AU  - Subbaramaiah K
FAU - Patel, Jay
AU  - Patel J
FAU - Masferrer, Jaime L
AU  - Masferrer JL
FAU - Deora, Aparna
AU  - Deora A
FAU - Hudis, Clifford
AU  - Hudis C
FAU - Thaler, Howard T
AU  - Thaler HT
FAU - Muller, William J
AU  - Muller WJ
FAU - Du, Baoheng
AU  - Du B
FAU - Brown, Anthony M C
AU  - Brown AM
FAU - Dannenberg, Andrew J
AU  - Dannenberg AJ
LA  - eng
GR  - CA89578/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Celecoxib
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Female
MH  - Humans
MH  - Isoenzymes/*antagonists & inhibitors/biosynthesis
MH  - Mammary Neoplasms, Experimental/enzymology/genetics/*prevention & control
MH  - Mammary Tumor Virus, Mouse/genetics
MH  - Membrane Proteins
MH  - Mice
MH  - Mice, Transgenic
MH  - Prostaglandin-Endoperoxide Synthases/biosynthesis
MH  - Pyrazoles
MH  - Receptor, ErbB-2/*antagonists & inhibitors/biosynthesis/genetics
MH  - Sulfonamides/*pharmacology
EDAT- 2002/10/03 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/10/03 04:00
PHST- 2002/10/03 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/10/03 04:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2002 Oct 1;62(19):5405-7.